# A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART

> **NCT01378156** · PHASE1 · COMPLETED · sponsor: **GeoVax, Inc.** · enrollment: 9 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **BIOLOGICAL:** JS7 plasmid DNA and MVA62B vaccine

## Key facts

- **NCT ID:** NCT01378156
- **Lead sponsor:** GeoVax, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2017-11-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01378156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01378156, "A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01378156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*